| Name |
|---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline currently includes: OpRegen, OPC1,...
Benzinga Rankings give you vital metrics on any stock – anytime.
You can purchase shares of Lineage Cell Therapeutics (AMEX:LCTX) through any online brokerage.
Other companies in Lineage Cell Therapeutics’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Moderna Inc (NASDAQ:MRNA).
Lineage Cell Therapeutics has a consensus price target of $5.43.
The stock price for Lineage Cell Therapeutics (AMEX: LCTX) is $0.9057 last updated October 13, 2026 at 2:25 PM EDT.
There are no upcoming dividends for Lineage Cell Therapeutics.
Lineage Cell Therapeutics does not have any upcoming earnings scheduled.
There is no upcoming split for Lineage Cell Therapeutics.
Lineage Cell Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the AMEX.
